title: Adiponectin and long-term mortality in coronary artery disease participants and controls.
abstract: OBJECTIVE
  Despite cardioprotective properties, studies investigating adiponectin as a cardiovascular disease marker led to conflicting results. We investigated in participants with stable coronary artery disease (CAD) and controls whether serum adiponectin was associated with long-term mortality, considering varying degrees of CAD severity.
  
  
  RESULTS
  A case-control design with prospective median follow-up of 8.1 years was used. Survival rates among 715 CAD men (aged 45-74 years) in increasing quartiles of serum adiponectin values were 87.5%, 85.6%, 76.4%, and 67.6%, respectively (P<0.001). Survival rates in 782 controls with adiponectin <9.1 µg/mL and ≥9.1 µg/mL (third quartile) were 95.3% and 91.0%, respectively (P=0.035). Adiponectin concentration above the highest quartile was associated with an increased risk of total and cardiovascular disease mortality in CAD patients (P=0.001 and P=0.001) and controls (P=0.02 and P=0.004). The associations among high adiponectin, total mortality, and cardiovascular disease mortality remained significant after multivariate adjustments for metabolic, cardiac, and CAD severity variables. No significant interaction was found among CAD patients, controls, and the relationship of adiponectin with mortality.
  
  
  CONCLUSIONS
  High serum adiponectin is a predictor of mortality, particularly from cardiovascular disease. This prognostic value remains significant whatever the severity of the CAD and the metabolic status and is not different among people with and without CAD.
authors.affiliation: Department of Cardiology, Rangueil Hospital, 1 avenue Jean Poulhes, 31000 Toulouse, France. shascoet.cardiotoulouse@yahoo.fr
authors.forename: Sébastien
authors.initials: S
authors.lastname: Hascoet
authors.forename: Meyer
authors.initials: M
authors.lastname: Elbaz
authors.forename: Vanina
authors.initials: V
authors.lastname: Bongard
authors.forename: Fréderic
authors.initials: F
authors.lastname: Bouisset
authors.forename: Céline
authors.initials: C
authors.lastname: Verdier
authors.forename: Cécile
authors.initials: C
authors.lastname: Vindis
authors.forename: Annelise
authors.initials: A
authors.lastname: Genoux
authors.forename: Dorota
authors.initials: D
authors.lastname: Taraszkiewicz
authors.forename: Bertrand
authors.initials: B
authors.lastname: Perret
authors.forename: Michel
authors.initials: M
authors.lastname: Galinier
authors.forename: Didier
authors.initials: D
authors.lastname: Carrié
authors.forename: Jean
authors.initials: J
authors.lastname: Ferrières
authors.forename: Jean Bernard
authors.initials: JB
authors.lastname: Ruidavets
mesh_terms: D052242:Adiponectin / Q000097:blood*; D000368:Aged; D015415:Biomarkers / Q000097:blood; D016022:Case-Control Studies; D002423:Cause of Death; D016009:Chi-Square Distribution; D003324:Coronary Artery Disease / Q000097:blood* / Q000175:diagnosis / Q000401:mortality* / Q000503:physiopathology; D018450:Disease Progression; D005500:Follow-Up Studies; D005602:France; D006801:Humans; D053208:Kaplan-Meier Estimate; D008297:Male; D008875:Middle Aged; D015999:Multivariate Analysis; D011379:Prognosis; D016016:Proportional Hazards Models; D011446:Prospective Studies; D018570:Risk Assessment; D012307:Risk Factors; D012720:Severity of Illness Index; D013997:Time Factors; D015854:Up-Regulation
chemical_list: C499918:ADIPOQ protein, human; D052242:Adiponectin; D015415:Biomarkers